Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Avono Health vs GoodRx

Avono Health
Graded #361

Lower grade

vs+10.899999999999991
GoodRx
Graded #116

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 58.7/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +50
30
80
Dose & formulationAvono Health +5
75
70
Clinical oversightAvono Health +11
80
69
Labs & monitoringAvono Health +2
53
51
FulfillmentGoodRx +10
71
81
Contract termsGoodRx +8
47
55
Avono Health · left barGoodRx · right bar

The numbers

MetricAvono HealthGoodRx
WeighScore58.7/10069.6/100
GradeCC
Scorecard rank#361#116
Semaglutide$269/mo (compounded)Not disclosed
Tirzepatide$349/mo (compounded)$299/mo (brand Zepbound)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Avono Health

Graded #361 · C

Strengths

  • Transparent tiered pricing from $179/mo (microdose semaglutide injection)
  • Full compounded range — semaglutide and tirzepatide, injection and oral, microdose and standard
  • Free and discreet shipping; 24/7/365 messaging support; 100% online
  • US-licensed clinicians and pharmacies; bundle discounts at 3/6/12 months

Where it loses points

  • Medications are compounded, not FDA-approved brand-name
  • Compounding pharmacy not publicly named
  • State availability not published
  • Newer brand with limited independent review history
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard